THE European Medicines Agency (EMA) met with European Union member states this week to develop principles around evaluation and monitoring of medicines sharing subsequent to Britain's exit from the EU.
They determined to provide business continuity, a high level of quality of scientific assessment and legal compliance as well as ensuring knowledge retention, ease of implementation and both medium and long-term sustainability.
The above article was sent to subscribers in Pharmacy Daily's issue from 03 May 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 May 17
